Status:
UNKNOWN
Neurophysiological, Biomolecular and Psychological Aspects of Erenumab Treatment in Chronic Migraine
Lead Sponsor:
IRCCS National Neurological Institute "C. Mondino" Foundation
Conditions:
Chronic Migraine
Eligibility:
All Genders
18-65 years
Brief Summary
Monoclonal antibodies (mABs) targeting calcitonin gene-related peptide (CGRP) proved effective in the preventive treatment of episodic and chronic migraine as well as in difficult-to-treat patients su...
Detailed Description
This study consisted of a first screening visit with a Neurologist of the Headache Science Centre of the IRCCS Mondino Foundation, during which a full neurological and general examination was performe...
Eligibility Criteria
Inclusion
- age 18 to 65 years
- history of CM or CM+MO for at least 12 months prior to enrollment \[10\]
- previous failure of at least two different pharmacological classes of preventive therapies
Exclusion
- other neurologic or neuropsychiatric diseases
- other chronic painful syndromes
- other types of primary or secondary headaches
- use of more than one preventive medication at baseline
- previous reported adverse reaction to latex
- pregnancy or lactation
Key Trial Info
Start Date :
January 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04361721
Start Date
January 15 2020
End Date
June 30 2021
Last Update
April 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Mondino Foundation
Pavia, Italy, 27100